Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multi-cohort study of Rinatabart Sesutecan in advanced non-small cell lung cancer
CTR20260819Phase 2Active
- Sponsor
- Jinmai Anbo Biopharmaceutical
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rinatabart sesutecan in non-small cell lung cancer (NSCLC), sponsored by Jinmai Anbo Biopharmaceutical. Started Aug 2026; status: active.
02
Drugs
rinatabart sesutecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20260819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260819.